Brigatinib is a next-generation ALK TKI designed to have potent and broad activity against ALK-positive rearrangements and a range of ALK resistance mutations.12, 13, 14 The recommended dose of brigatinib (180 mg once daily with 7-d lead-in at 90 mg once daily) was established in a multinational phase 1/2 study15 and confirmed in the phase 2 ALTA (ALK in Lung Cancer Trial of AP26113) trial in crizotinib-refractory patients with ALK+ NSCLC.16 This evidence concerns the gene ALK and non-small cell lung carcinoma.